Google NewsAroa Biosurgery (ASX:ARX) Beats FY26 Guidance as Myriad Drives 54% Growth Surge - Kalkine
Aroa Biosurgery (ASX:ARX) Beats FY26 Guidance as Myriad Drives 54% Growth Surge Kalkine
AROA BIOSURGERY ORDINARY (ARX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
StockheadLong Shortz with Aroa Biosurgery: ARX delivers breakout FY26 results
Aroa has delivered breakout FY26 results, with record revenue, strong EBITDA growth and rising momentum from its Myriad product portfolio. ... Read More The post Long Shortz with Aroa Biosurgery: ARX delivers breakout FY26 results appeared first on Stockhead.
ASX
KalkineWhat’s Fueling Fresh Buzz Around Aroa BioSurgery?
Highlights Aroa BioSurgery continues expanding its regenerative wound care footprint across international healthcare markets. Product innovation and hospital adoption trends remain central to the company’s commercial momentum. Regulatory pathways, healthcare spending trends and manufacturing execution continue shaping sector sentiment. Aroa BioSurgery continues expanding within regenerative healthcare as innovation, hospital adoption trends and healthcare demand shape attention ac...
Aroa beats FY26 guidance as Myriad drives 54% growth surge
Aroa delivers strong FY26, beating revenue and earnings guidance as rapid growth from its Myriad wound care portfolio continues to ... Read More The post Aroa beats FY26 guidance as Myriad drives 54% growth surge appeared first on Stockhead.
Small CapsAroa Biosurgery (ASX:ARX) prints NZ$12.6m EBITDA then guides it lower for FY27 - Stocks Down Under
Aroa Biosurgery (ASX:ARX) prints NZ$12.6m EBITDA then guides it lower for FY27 Stocks Down Under
Aroa beats guidance as Myriad growth drives strong FY26 performance
Aroa Biosurgery has topped NZ$100 million in annual revenue for the first time, beating FY26 guidance on sales and earnings ... Read More The post Aroa beats guidance as Myriad growth drives strong FY26 performance appeared first on Stockhead.
Aroa Biosurgery (ASX:ARX) Guidance smashed by A$4m, Myriad growth at 52% does the heavy lifting - Stocks Down Under
Aroa Biosurgery (ASX:ARX) Guidance smashed by A$4m, Myriad growth at 52% does the heavy lifting Stocks Down Under
Canaccord in tune with Aroa Biosurgery on Symphony’s US opportunity
Canaccord sees meaningful upside in Aroa Biosurgery, as US reimbursement reforms create a more favourable backdrop for its upcoming Symphony ... Read More The post Canaccord in tune with Aroa Biosurgery on Symphony’s US opportunity appeared first on Stockhead.
Stock Market Spotlight: Breakthrough in Wound Care as (ASX:ARX) Advances Trial
Highlights Symphony study reaches key clinical milestone Improved healing outcomes seen in trial group Strengthens pathway toward wider medical adoption Aroa Biosurgery has completed a major clinical study for its Symphony product, highlighting improved healing in complex diabetic wounds and reinforcing its position within advanced wound care innovation. Aroa Biosurgery Strengthens Clinical Footprint with Symphony Study Completion Aroa Biosurgery (ASX:ARX) has taken a meaningful step fo...
Study Demonstrates Effectiveness & Economic Value of Myriad
other announcement
Aroa Biosurgery H1 Results Webinar & Investor Event
other announcement
Paul Shearer to join Aroa Board and John Pinion to Retire
other announcement
Change of Director's Interest Notice - BW
director_dealing announcement
Change of Director's Interest Notice - PM
director_dealing announcement
Change of Director's Interest Notice - JP
director_dealing announcement
Change of Director's Interest Notice - JM
director_dealing announcement
Change of Director's Interest Notice - BW
director_dealing announcement
Notification of Cessation of Securities - Correction
other announcement
Notice of AGM Date and Director Nomination Closing Date
other announcement